



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

**\*BIBDATASHEET\***

CONFIRMATION NO. 2403

Bib Data Sheet

SERIAL NUMBER 10/076,575	FILING DATE 02/08/2002  RULE	CLASS 514	GROUP ART UNIT 1624	ATTORNEY DOCKET NO. 5698.220-US
-----------------------------	---------------------------------------	--------------	------------------------	------------------------------------

APPLICANTS

Lone Jeppesen, Virum, DENMARK;  
Paul Stanley Bury, Kobenhavn, DENMARK;  
Per Sauerberg, Farum, DENMARK;

**\*\* CONTINUING DATA \*\*\*\*\***  
This application is a DIV of 09/419,761 10/19/1999 PAT 6,468,996  
and claims benefit of 60/105,912 10/28/1998

**\*\* FOREIGN APPLICATIONS \*\*\*\*\***  
DENMARK PA 1998 01352 10/21/1998

IF REQUIRED, FOREIGN FILING LICENSE GRANTED  
**\*\* 03/07/2002**

Foreign Priority claimed 35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no Verified and Acknowledged <u>Brenda Coleman</u> <u>BC</u> Examiner's Signature Initials	STATE OR COUNTRY DENMARK	SHEETS DRAWING 0	TOTAL CLAIMS 10	INDEPENDENT CLAIMS 1
---	--------------------------------	------------------------	-----------------------	----------------------------

ADDRESS  
Reza Green, Esq.  
Novo Nordisk of North America, Inc.  
100 College Rd. W.  
Princeton, NJ  
08540-6604

TITLE  
Substituted hetero-polycyclic compounds as PPARalpha and PPARgamma activators

FILING FEE  RECEIVED 740	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
-----------------------------------	---	---